Thursday - April 10, 2025
Johnson & Johnson: Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized Myasthenia Gravis
January 10, 2025
NEW BRUNSWICK, New Jersey, Jan. 10 (TNSres) -- Johnson and Johnson issued the following news release:

* * *

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study

Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positive adult patients: anti-AChR, anti-MuSK, anti-LRP4

* * *

SPRING HOUSE, Pa., (January 9, 2025) - Johnson & Johnson (NYSE: JNJ) . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products